The "Aerosol Delivery Devices Market by Product, Application and Distribution Channel: Global Opportunity Analysis and Industry Forecast, 2020-2027" report has been added to ResearchAndMarkets.com's offering.
The global aerosol delivery devices market was valued at $31,463.9 million in 2019, and is projected to reach $46,728.7 million by 2027, registering a CAGR of 4.9% from 2020 to 2027.
Aerosol delivery devices are hand-held, portable drug delivery devices. They consist of suspension of solid or liquid particles in a carrier gas, which makes feasible for treatment of respiratory and non-respiratory diseases. There are different forms of drugs available for aerosol drug delivery such as dry powder, solution, and suspension. It is the most advanced mode of drug administration in which aerosolized drug is directly delivered to lungs to offer a systemic effect. Aerosol delivery devices are available in three types, namely, dry powder inhalers, metered dose inhalers, and nebulizers. Aerosol drug delivery is a natural therapy and easiest way to treat respiratory diseases such as asthma, COPD, and cystic fibrosis. Moreover, it is used to deliver insulin, analgesic medications, and other drugs as well.
Rise in prevalence of asthma, COPD, and other respiratory disorders, an increase in smoking population, ease of administration of drug with aerosol delivery devices, rise in demand for metered-dose inhalers, technological advancements in inhaler devices, and rise in geriatric population are the key factors that fuel growth of the global aerosol delivery devices market. For instance, according to the WHO, in 2018, more than 339 million people were affected by asthma worldwide. Moreover, rise in adoption of aerosol delivery devices by patients, an increase in patient awareness toward inhalation therapy, surge in preference of pulmonary route of drug delivery, rise in urbanization and pollution levels, an increase in incidences of preterm births and lifestyle changes, and increase in the number of R&D activities to develop ideal inhalation therapy are other factors that contribute toward growth of the market. However, complications and side-effects associated with drug inhalation and high cost associated with nebulizers are expected to hinder growth of the market.
The global aerosol delivery devices market is segmented into product, application, and distribution channel. By product, the market is categorized into dry powder inhalers, metered dose inhalers, and nebulizers. The dry powder inhalers segment is further bifurcated into single dose inhalers and multi dose inhalers. The metered dose inhalers segment is further divided into conventional pressurized inhalers and soft mist inhalers. The nebulizers segment is further categorized into jet nebulizers, ultrasonic wave nebulizers, and vibrating mesh nebulizers.
On the basis of application, the market is segregated into asthma, chronic obstructive pulmonary disease, cystic fibrosis, and non-respiratory diseases. The non-respiratory diseases segment is further divided is into diabetes, analgesia, and Parkinson's disease. Depending on distribution channel, the market is classified into retail pharmacies, hospital pharmacies, and e-commerce. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Benefits for Stakeholders
The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
It offers a quantitative analysis from 2019 to 2027, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
A comprehensive analysis of four regions is provided to determine the existing opportunities.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
Increase in Air Pollution
Advantages Over Conventional Drug Delivery Devices
Increase in Prevalence of Copd and Asthma
Rise in Government Initiatives
High Cost of Asthma and Copd Treatments
Lack of Access in Underdeveloped Countries
Growth Opportunities in Emerging Markets
Glaxosmithkline Plc (GSK)
Johnson & Johnson (Actelion Pharmaceuticals Ltd)
Koninklijke Philips N.V.
Merck & Co. Inc.
Metall Zug Group (Clement Clarke International Ltd)
Recipharm AB (Bespak)
Teva Pharmaceutical Industries Limited
Vectura Group Plc
Heitkamp & Thumann KG (H&T Presspart)
For more information about this report visit https://www.researchandmarkets.com/r/bx4zd6
View source version on businesswire.com: https://www.businesswire.com/news/home/20201020005714/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900